NewLimit

Overview

NewLimit is a startup focused on epigenetic reprogramming to treat age-related diseases, co-founded by Jacob Kimmel approximately four years before UNLOCK 2026. The company uses AI to simulate the effects of perturbations across human cell types, with experimental work conducted in primary human cells rather than cell lines — a distinction Kimmel emphasizes as essential for translational relevance.

The scientific ambition is significant: if NewLimit's platform succeeds across even a small number of cell types, the result could add healthy years to the median American lifespan. Kimmel has emerged as a thoughtful skeptic of certain AI hype narratives in drug discovery; he argues that target identification remains the fundamental bottleneck and expresses skepticism toward AI approaches that rely primarily on reasoning over existing literature rather than generating new experimental data.